13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino - LARVOL DELTA

PRO-PCV-1002: A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: Sinovac Research and Development Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2025 ➔ Mar 2025

Trial completion • Trial completion date • Infectious Disease • Pneumococcal Infections

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China. (PubMed, Vaccines (Basel)) - P3 | "Opsonophagocytic activity (OPA)-related geometric mean titers (GMTs) were superior for PCV13i against serotypes 7F (39,583 vs. 17,249, p < 0.001) and 19F (1517 vs. 983, p = 0.028), but lower for serotype 5 (13 vs. 93, p < 0.001). PCV13i demonstrated non-inferior immunogenicity and an acceptable safety profile in 12-23-month-old children."

Clinical • Journal • P3 data • Dermatology • Infectious Disease • Pneumococcal Infections

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P3 trial • Infectious Disease • Pneumococcal Infections

PRO-PCV-1002: A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=140 | Active, not recruiting | Sponsor: Sinovac Research and Development Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

PRO-PCV-1002: A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Sinovac Research and Development Co., Ltd. | Trial completion date: Apr 2025 ➔ Jul 2025 | Trial primary completion date: Sep 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=310 | Completed | Sponsor: Sinovac Life Sciences Co., Ltd. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=310 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

PRO-PCV-1002: A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: Sinovac Research and Development Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (clinicaltrials.gov) - P3 | N=3420 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=140 | Not yet recruiting | Sponsor: Sinovac Research and Development Co., Ltd.

New P1 trial • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=310 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Dec 2022 ➔ Dec 2023

Enrollment open • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (clinicaltrials.gov) - P3 | N=3420 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2023 ➔ Nov 2024 | Trial primary completion date: Aug 2022 ➔ Mar 2022

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

PICTON: Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (clinicaltrials.gov) - P1 | N=237 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2021 ➔ Aug 2022

Trial completion • Trial completion date • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=310 | Not yet recruiting | Sponsor: Sinovac Life Sciences Co., Ltd. | Initiation date: Dec 2021 ➔ Sep 2022 | Trial primary completion date: Jan 2022 ➔ Dec 2022

Trial initiation date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1; N=310; Not yet recruiting; Sponsor: Sinovac Research and Development Co., Ltd.

Clinical • New P1 trial • Infectious Disease • Pneumococcal Infections

PICTON: Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (clinicaltrials.gov) - P1; N=237; Active, not recruiting; Sponsor: CanSino Biologics Inc.; Trial completion date: Jun 2021 ➔ Dec 2021; Trial primary completion date: May 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (clinicaltrials.gov) - P3; N=3420; Recruiting; Sponsor: CanSino Biologics Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Pneumococcal Infections

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (clinicaltrials.gov) - P3; N=3420; Not yet recruiting; Sponsor: CanSino Biologics Inc.

New P3 trial • Infectious Disease • Pneumococcal Infections